ArticleSurgery2026
Patient preferences in papillary thyroid microcarcinoma management are driven by aversion toward complications rather than treatment pathway.
Article in Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Ablative Technologies for Thyroid Nodules: A Health Technology Assessment.Ontario health technology assessment series · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPapillary thyroid microcarcinomas carry an excellent prognosis, making patient preferences and cost-effectiveness important determinants of treatment selection. To conduct cost-effectiveness analyses, quality-adjusted life year weights for papillary thyroid microcarcinoma treatments must be derived. Our objective was to estimate the quality-adjusted life year weights of common papillary thyroid microcarcinoma treatment scenarios.
methodsThis study used 10 previously published papillary thyroid microcarcinoma clinical vignettes describing active surveillance, radiofrequency ablation, partial thyroidectomy, and total thyroidectomy, along with potential complications (progression, vocal cord palsy, hypocalcemia). Quality-adjusted life year weights were derived using a time trade-off instrument administered to thyroid cancer survivors. Quality-adjusted life year weights were compared using within-subjects repeated measures analysis of variance and paired Wilcoxon rank-sum tests. The cohort was powered to detect a minimal important difference with an effect size of 0.5 (ie, 0.04 quality-adjusted life year).
resultsData from 101 thyroid cancer survivors were collected. Median quality-adjusted life year weights for uncomplicated treatment scenarios ranged from 0.975 to 0.992 and were not significantly different between treatments (P = .15). Treatment complications resulted in significantly lower quality-adjusted life year weights across all treatment strategies (P < .01) except active surveillance (P = .72).
conclusionQuality-adjusted life year weights were comparable between the uncomplicated versions all 4 treatment pathways, suggesting that patient treatment preferences for papillary thyroid microcarcinoma are driven by aversion to treatment complications, rather than an inclination toward the experience of the treatments themselves. These quality-adjusted life year weights may be readily incorporated into value assessments for papillary thyroid microcarcinoma treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.